Jack O'Brien
Dermatology · Dallas, TXNPI 1639600596
Payments from drug & device makers
Across 46 payments — averaging $1207.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Incyte Corporation$39K
- UCB, Inc.$9K
- Novartis$7K
- Boehringer Ingelheim$260
- Regeneron Healthcare Solutions, Inc.$109
- AbbVie$100
- plus $31 from 1 others
What the payments were for
- Consulting fees$21,10082%
- Travel & lodging$3,15112%
- Food & beverage$1,5986%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Incyte Corporation | 16 | $39,147 |
| UCB, Inc. | 16 | $9,378 |
| Novartis | 8 | $6,529 |
| Boehringer Ingelheim | 3 | $260 |
| Regeneron Healthcare Solutions, Inc. | 1 | $109 |
| AbbVie | 1 | $100 |
| Gilead | 1 | $31 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$55,553 in reported general payments places this provider in the 90th percentile of 1,098 dermatology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 77 | $1,020,125 |
| Cosentyx Unoready PenSecukinumab | 27 | $340,591 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 28 | $315,992 |
| Dupixent PenDupilumab | 64 | $243,024 |
| Enbrel SureclickEtanercept | 11 | $95,820 |
| Cosentyx Sensoready PenSecukinumab | 12 | $87,482 |
| Dupixent SyringeDupilumab | 15 | $54,579 |
| Clobetasol Propionate | 151 | $5,842 |
| Tacrolimus | 34 | $4,159 |
| Triamcinolone Acetonide | 227 | $3,562 |
| Clindamycin Phosphate | 85 | $2,783 |
| Ketoconazole | 200 | $2,757 |
| Doxycycline Hyclate | 102 | $2,691 |
| Tretinoin | 27 | $2,251 |
| ValacyclovirValacyclovir Hcl | 45 | $1,369 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Dallas
- Jennifer CatherDallas$4.9M
- Martin MenterDallas$3.7M
- So Yeon PaekDallas$3.5M
- Ross RaduskyDallas$3.3M
- Joseph MerolaDallas$2.1M
- William AbramovitsDallas$1.8M
- Donald GlassDallas$847K
- Kristel PolderDallas$761K
- Mary HornerDallas$457K
- Gregory PetersonDallas$412K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.